

Innovative Technology. Practice Excellence.

Backed by Alcon's robust support capabilities, the ALLEGRETTO WAVE® Eye-Q Laser delivers excellent efficiency, accuracy and patient outcomes to enhance your practice performance.



Learn more about how the ALLEGRETTO WAVE® Eye-Q Laser can benefit your practice.

www.alconrefractive.com

FDA Approved Clinical Results


Proven Powerful Hyperopic Outcomes

FDA clinical trial results for *Wavefront Optimized*® correction clearly demonstrate why the ALLEGRETTO WAVE® Eye-Q Laser continues to maintain its category leadership.

After *Wavefront Optimized*® LASIK, patients reported an improvement in glare from bright lights, light sensitivity, and night driving glare. The percent of subjects reporting “none” or “mild” of these symptoms improved after treatment.¹


Wavefront Optimized® procedures use the power of *PerfectPulse Technology*® to ensure excellent hyperopia treatment outcomes. This personalized approach enables precise and accurate ablations tailored to each patient's refractive error.

Uncorrected Visual Acuity (UCVA) Effectiveness – Hyperopia




More than 67% of patients saw 20/20 or better without glasses after treatment. 95% of patients saw 20/40 or better without glasses after treatment.¹

Best Spectacle Corrected Visual Acuity (BSCVA) – Hyperopia



Nearly 90% of patients remained unchanged or gained one or more lines of BSCVA vision.¹

Change in Post-UCVA vs. Pre-BSCVA – Hyperopia



55% of patients saw at least as good or better without visual aids after the treatment than before with their glasses or contact lenses.¹

For International Distribution Only.

6201 South Freeway, Fort Worth, Texas 76134
©2009 ALCON, Inc. 4/09
ALL160B


Myopic Clinical Outcomes Summary for *Wavefront Optimized*[®] and Wavefront-Guided Study Groups²

For effective treatment of myopia, *Wavefront Optimized*[®] and Wavefront-Guided procedures enable the development of precise, personalized vision correction.

- Wavefront-Guided LASIK is proven to reduce aberrations, specifically trefoil and spherical aberrations (patients up to -4.0 D or more than 0.3 μm RMSH)
- *Wavefront Optimized*[®] LASIK also reduced aberrations in patients with pre-op RMSH < 0.4 μm
- No symptomatic increase in aberrations observed after *Wavefront Optimized*[®] or Wavefront-Guided LASIK
- Low contrast acuity improved in patients with significant pre-op RMSH
- Both Wavefront-Guided and *Wavefront Optimized*[®] LASIK had a low rate of enhancements
- More than 97% of patients would probably or highly recommend the treatment to a friend
- More than 92% of patients noted their visual quality as good or excellent after treatment

More than 97% of both patient groups remained unchanged or gained one or more lines of BSCVA vision.

Uncorrected Visual Acuity (UCVA) Effectiveness - Myopia




Both groups demonstrated similar performance for visual acuity. In both groups, 93% of patients achieved UCVA 20/20 or better after treatment.²

A Broad Spectrum of Myopic Vision Correction

The WaveLight[®] ALLEGRETTO Wave[®] Eye-Q Laser in conjunction with the ALLEGRO Analyzer[®] aberrometer provides effective, customized treatments for patients with higher order aberrations and complex vision correction needs.


All eyes naturally have higher order spherical aberrations. In eyes with relatively normal levels of higher order spherical aberrations, a *Wavefront Optimized*[®] treatment has been shown to be effective in producing excellent visual outcomes.²

Best Spectacle Corrected Visual Acuity (BSCVA) - Myopia



More than 97% of both patient groups remained unchanged or gained one or more lines of BSCVA vision. Over 50% of all patients gained at least one line over BSCVA.²

Change in post-UCVA vs. pre-BSCVA - Myopia



85% of patients saw at least as good or better without visual aids after the treatment (*Wavefront Optimized*[®] or Wavefront-Guided) than before with their glasses or contact lenses.²

1. FDA Clinical Trials: *Wavefront Optimized*[®] for Hyperopia (<http://www.fda.gov/cdrh/pdf3/P030008.html>)

2. FDA Clinical Trials: *Wavefront Optimized*[®] and Wavefront-Guided for Myopia plus astigmatism (<http://www.fda.gov/cdrh/pdf2/P0200505004b.pdf>)